IP Library Granted Patent US 11,672,860
Granted Patent B2
US 11,672,860 · App. 16/671,279 · Granted Jun 13, 2023

Drug eluting matrix on analyte indicator

Inventors: Philip Huffstetler (Germantown, MD); Sanat Mohanty (Germantown, MD); Robert Attwood (Germantown, MD)
Assignee: Senseonics, Incorporated
A61K41/0042A61B5/002A61B5/1451A61B5/1459A61B5/14532A61K31/192A61K31/573A61K31/616A61N5/062
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,672,860
App. No.
16/671,279
Granted
Jun 13, 2023
Kind
B2
Abstract

A sensor that may be implanted within a living animal (e.g., a human) and may be used to measure an analyte (e.g., glucose or oxygen) in a medium (e.g., interstitial fluid, blood, or intraperitoneal fluid) within the animal. The sensor may include a sensor housing and an analyte indicator covering at least a portion of the sensor housing. The sensor may include a drug-eluting matrix that covers at least a portion of the analyte indicator. The drug-eluting matrix may include one or more openings configured to allow the medium to pass through the drug-eluting matrix and come into contact with the analyte indicator. The sensor may include one or more therapeutic agents. The one or more therapeutic agents may reduce deterioration of the analyte indicator. The one or more therapeutic agents may be incorporated within the drug-eluting matrix.

Claims (26)

1. A sensor for measurement of an analyte in a medium within a living animal, the sensor comprising:

a sensor housing;

an analyte indicator covering at least a portion of the sensor housing, wherein the analyte indicator comprises one or more indicator molecules that reversibly bind the analyte and exhibit a detectable property indicative of whether the analyte is bound;

a drug-eluting matrix that covers only a portion of the analyte indicator, wherein the drug-eluting matrix includes one or more openings configured to allow the medium to pass through the drug-eluting matrix and come into contact with the analyte indicator, and the one or more openings of the drug-eluting matrix result in the drug-eluting matrix not covering one or more portions of the analyte indicator; and

one or more therapeutic agents that reduce deterioration of the analyte indicator and are dispersed within the drug-eluting matrix.

2. The sensor of claim 1 , wherein the sensor is implantable within a living animal.

3. The sensor of claim 1 , wherein the drug-eluting matrix covers at least a portion of the sensor housing.

4. The sensor of claim 1 , wherein the druq-elutinq matrix is a druq-elutinq polymer matrix, and wherein one or more of the therapeutic agents are incorporated within the drug-eluting polymer matrix via one or more covalent bonds that break in the presence of aqueous media and release the one or more therapeutic agents.

5. The sensor of claim 1 , wherein the druq-elutinq matrix is a druq-elutinq polymer matrix, and wherein one or more of the therapeutic agents are incorporated within the drug-eluting polymer matrix via one or more covalent bonds that break through exposure to light and release the one or more therapeutic agents.

6. The sensor of claim 5 , further comprising a light source, wherein the covalent bonds break through exposure to light emitted by the light source.

7. The sensor of claim 1 , wherein the one or more therapeutic agents include an anti-inflammatory drug.

8. The sensor of claim 7 , wherein the anti-inflammatory drug is a non-steroidal anti-inflammatory drug.

9. The sensor of claim 8 , wherein the non-steroidal anti-inflammatory drug is acetylsalicylic acid.

10. The sensor of claim 8 , wherein the non-steroidal anti-inflammatory drug is isobutylphenylpropanoic acid.

11. The sensor of claim 1 , wherein the one or more therapeutic agents include a glucocorticoid.

12. The sensor of claim 1 , wherein the one or more therapeutic agents include one or more of dexamethasone, triamcinolone, betamethasone, methylprednisolone, beclometasone, fludrocortisone, derivatives thereof, and analogs thereof.

13. The sensor of claim 1 , wherein the one or more therapeutic agents reduce oxidation of the analyte indicator.

14. The sensor of claim 1 , wherein the analyte indicator is a graft including indicator molecules.

15. The sensor of claim 1 , further comprising a layer of a catalyst capable of converting hydrogen peroxide into water and oxygen on at least a portion of the analyte indicator.

16. The sensor of claim 1 , further comprising:

a light source within the sensor housing configured to emit excitation light; and

a photodetector within the sensor housing, wherein the photodetector is sensitive to light emitted by the one or more indicator molecules and configured to generate a signal indicative of the amount of the analyte in the medium within the living animal.

17. The sensor of claim 1 , wherein the one or more openings comprise a plurality of openings.

18. The sensor of claim 1 , wherein the one or more openings comprise one or more openings having a circular, oval, square, pear, or diamond shape.

19. The sensor of claim 1 , wherein the one or more openings comprise relatively large openings and relatively small openings.

20. The sensor of claim 1 , wherein the one or more openings comprise rows of openings.

Assignments (8)
SECURITY INTEREST Recorded Sep 11, 2023
From: SENSEONICS, INCORPORATED
To: HERCULES CAPITAL, INC.
Reel/Frame 064866/0963 →
RELEASE OF SECURITY INTEREST Recorded Sep 7, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
To: SENSEONICS, INCORPORATED; SENSEONICS HOLDINGS, INC.
Reel/Frame 064834/0962 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2023
From: HUFFSTETLER, PHILIP; MOHANTY, SANAT; ATTWOOD, ROBERT
To: SENSEONICS, INCORPORATED
Reel/Frame 063371/0897 →
RELEASE OF SECURITY INTEREST Recorded Apr 14, 2023
From: ALTER DOMUS (US) LLC, AS COLLATERAL AGENT
To: SENSEONICS HOLDINGS, INC.; SENSEONICS, INCORPORATED
Reel/Frame 063338/0890 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Aug 14, 2020
From: SENSEONICS, INCORPORATED
To: ALTER DOMUS (US) LLC, AS COLLATERAL AGENT
Reel/Frame 053496/0292 →
RELEASE OF SECURITY INTEREST IN PATENTS AND TRADEMARKS Recorded Aug 14, 2020
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, COLLATERAL AGENT
To: SENSEONICS, INCORPORATED; SENSEONICS HOLDINGS, INC.
Reel/Frame 053498/0275 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT - FIRST LIEN Recorded Apr 24, 2020
From: SENSEONICS, INCORPORATED; SENSEONICS HOLDINGS, INC.
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 052492/0109 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT -SECOND LIEN Recorded Apr 24, 2020
From: SENSEONICS, INCORPORATED; SENSEONICS HOLDINGS, INC.
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 052490/0160 →